Fenofibrate: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='97/977745/Cv/1'> | ||
Fenofibrate (sold under the brand names Tricor, Fenobrat etc.), is an oral medication of the fibrate class used to treat abnormal blood lipid levels.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref> It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces to the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref><ref name="a3">PMID:20228404</ref><ref name="a4">PMID:31562117</ref> See also [https://en.wikipedia.org/wiki/Fenofibrate]. | Fenofibrate (sold under the brand names Tricor, Fenobrat etc.), is an oral medication of the fibrate class used to treat abnormal blood lipid levels.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref> It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces to the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref><ref name="a3">PMID:20228404</ref><ref name="a4">PMID:31562117</ref> See also [https://en.wikipedia.org/wiki/Fenofibrate]. | ||
Revision as of 15:54, 19 July 2023
Fenofibrate (sold under the brand names Tricor, Fenobrat etc.), is an oral medication of the fibrate class used to treat abnormal blood lipid levels.[1] It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces to the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.[1][2][3] See also [1].
|
| ||||||||||
ReferencesReferences
- ↑ 1.0 1.1 "Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ↑ Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1563-74. PMID:20228404 doi:10.1056/NEJMoa1001282
- ↑ Kim NH, Han KH, Choi J, Lee J, Kim SG. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019 Sep 27;366:l5125. PMID:31562117 doi:10.1136/bmj.l5125